Summary & Overview
CPT 0226U: Tru–Immune Neutralizing Antibody Assay
CPT code 0226U designates a Proprietary Laboratory Analyses (PLA) test for the Tru–ImmuneTM assay from Ethos Laboratories, GenScript® USA, which assesses the neutralizing capacity of antibodies against SARS–CoV–2 in a blood sample. As a PLA code, 0226U applies only to this specific manufacturer's test and is used by laboratories and payers to identify the unique service.
This national-level overview addresses coverage and billing considerations for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical purpose of the assay, typical sites where the service is performed, and the implications of a PLA designation for coding clarity and payer identification.
The publication summarizes benchmarks and policy-relevant points: how PLA coding distinguishes manufacturer-specific proprietary tests, the role of neutralizing antibody measurement in post-infection and post-vaccination assessment, and the operational coding elements laboratories must report. It also flags areas where payer policy language or national reimbursement guidance commonly affects adoption and claims handling. Data not available in the input are noted where applicable, and readers will gain a concise reference for billing, coding, and clinical context related to CPT code 0226U.
Billing Code Overview
CPT code 0226U is a Proprietary Laboratory Analyses (PLA) code reported for the Tru–ImmuneTM test from Ethos Laboratories by GenScript® USA. The test measures the current neutralizing capacity of antibodies against the SARS–CoV–2 virus in a blood sample and is specific to this single manufacturer's assay.
Service type: Proprietary laboratory diagnostic test (neutralizing antibody assay)
Typical site of service: Clinical laboratory or reference laboratory
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient presenting for assessment of immune protection against SARS–CoV–2, either after recent vaccination, prior infection, or exposure, or when evaluating immune status before immunosuppressive therapy. The clinician orders the Tru–Immune™ neutralizing antibody test performed by Ethos Laboratories (GenScript® USA). A phlebotomy appointment is scheduled at an outpatient laboratory, hospital outpatient phlebotomy unit, or ambulatory clinic. A blood specimen (serum or plasma per lab instructions) is collected, labeled with patient identifiers, and shipped to Ethos Laboratories under required temperature and handling conditions.
Laboratory processing includes receipt, accessioning, and performing the proprietary neutralization assay that quantifies antibody-mediated inhibition of SARS–CoV–2 spike protein–ACE2 interaction. Results are reported as a numeric neutralizing antibody level and interpretive comment about current neutralizing capacity. The result is routed to the ordering provider via the electronic health record or secure report; clinicians use the result for counseling on infection risk, need for booster vaccination, or managing immunosuppressed patients. Typical sites of service are outpatient laboratory, hospital outpatient, ambulatory clinic, or mobile phlebotomy services. Common clinical indications include post-vaccination immune assessment, evaluation after confirmed or suspected SARS–CoV–2 infection, assessment in immunocompromised patients, and pre-exposure risk evaluation for high-risk procedures or travel.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|